Sie sind auf Seite 1von 4
Twilight Litaka Pharma Limited in Pune - 411 005. 1. Off, : Himalaya Estate, 16-A, Shivali Nagar, Te No 020'50261700701 / 02, Fax : 020-2553 3211. TL PL, Email : ho@uipl.co.in Website : www.twilightltaka.com Registered Office of the Company is B-22, Block, M.LD.C. Pimpri, Pune ~ 411 018 DATE 17" February, 2014 . TO, BSE LTD, PHIROZE JEEJEEBHOY TOWERS DALAL STREET, FORT MUMBAI 400 001 Designated “+91 22 2272 3131/2272 0037/2079 Dal T2a73 206172272 2039 2372 Fax Numbers | 3719/2272 1278 / 2272 1557/2272 3354/2272 3577 Ref: - Our Scrip Code No. 506985 Dear Sir/Madam Fleas find enclosed herewith a copy of the Un-Auited Financial Result of our Company for the quarter ended 31* December, 2013. Kindly acknowledge receipt of the same. Thanking you For Tyfilight Litaka Pharma Ltd Gopal Ramourti Managing Director }9, Andher-Kurla Road, Saki Naka, Andher (E), Mumbal - 400 072. 847 / 48 / 2851 3538, Fax : 91-22-2850 5867 imin. Off. : 206, Shival Ind. Est, . Tel. No.: 6691 ‘Twilght Ltaka Pharma Limited Regd Office "B22," BLOCK, MIOC PIMPRI, PUNE-411018, Pose eta PART! JNAUDITED FINANCIAL RE: A THE QUARTER ENDED 31st DECEMBER, 201 (s,m tes) a Particulars Provious No, ‘Quarter End ‘Yoar To Date Yoor Ended eat] To 01.10.2013 | 01.07.2013 | o1.10.2012 01.07.2012 | 30.06.2019 To To To |o.o72013 To] | To (For 1 1.122018 | 20.082013 | 422012 | 34.12.2013 | 31.12.2012 | Menthe {Unausited)| (Unaudited) | (Unaueited) | (Unaudited) | (Unaudited) | Audited) 7 ]&- Net Sales ticome Fam Operations 826.00, 1008.2] «S886.63 1807-12] 14681.80) — 23,839.43) lo. ther Operating Income 2 |expenditure ls ncreatoicocoace in stock in rade & WIP 12012] 14556] 138.83] 255.68] agn.2 251 lb Consumption of Raw materia, ssi] 24700] aasa.s7| —aas-36] sora) s8,542.17 Je Purchase of raded goods. coro] 608.90] tester] —tzae91| ase to] it 09875 ld Employee cost, ‘3rs8] rsa] 15810] gar] “atzs| tts] la Deprecaten 108.25, 11025] rza.as] “218.60 eis] saa. Otverexpenature 21525] ssozes] sorta] ve17.g0] —sa57se| 7.86824 lg. Expenatoe (at) tos] 2asz0i] —ss2277) 380249] 1390723] apt07.60 4 |Profitftom Operations before Other income, Intorost land Exceptional tems (1:2), 21e4a] 145099] 20386 1665.37 74.57 | -s2s0.t0 4 [omer income “ol 23.0) 1901 5 |Profithefore interest & Exceptional tems (24) -2144a]_ soso] 274.10 | — -tess.s7|_ese.s7| —-s240.05 6 |interst rags] 1884] 015.27 28.49] 2010.5 9725| ProfiL.oss) ater intrest, but Before Exceptional 7 items =) (22743)) (1.46643 rasan] (1600.86) (1321.50)] 6946.20 8 |Excoptional tems 41,758.53] oi(Loss) from Ordinary Activities before tax 2 ira) (22r43)(n4e64a] — ae.z7]¢192.06)] (4.321.88)| (17.100. 10 [Tax Expenses 0.00] 618] 11 Profiit.oss) rom Ordinary Activites aftrtax (9-10) | (227.43}| (1.466.43)) (739.17)| (1.688.86)] (1,32188]| 7,098.78 12 |traonsnary tors (nat of tax expense) : - : 5 18 Not Proft(Loss) forthe poriod (2z743)) (1466.43) (7a9.s7] (1.698.86)| (1,321-58)| (17,008.78) 14 [Paid Equty Share Captal fay ste o Rete) 123006] 1238.06 1230.05] 1230.05] 4298.00) | 12390 15 [Reserve excudngrovakation reserves 7283] 72.80] 18384.26 ‘7a.80] 18306.26| 1,021.22 18 fEarang per share PS) * [2 Bas and dlsted EPS before exesordinary wosz] eq] ees] 3m] 6a. items for he peroa * lb. Basic and died EPS ater extraordinary 92) 6s (209) sa] 68.90 items forthe pesed. INFORWATION FOR THE QUARTER ENDED st-rzzot3 | [PARTICULARS OF SHAREHOLDING 1 |Asoregate of nem promoter shaehosing umber of shares ‘eanaass] 2easaeds| zaces201| zeasteno] zoesazos]| 2446404) percentage of shareholing sre] sara] agar] a72| 0567] sar 2 [Promoters and Promoters Group sharonoting 23) Pledge Enoombored "moe ef saree tsaso] tsaso] —7e6806) 15360) 700nn8] 15380 Logie cieioes (=i tempinnteareet 40] 40529 405) 72. 435 Parcentge of shes (lee ta src esx i} Non Encunbered Nambor ef shes soross] soroee)aotoes|s0toss} sooea)—sovaee Heer ek telecine araa| 27.43 2742 2742| 2742} 27.42] [_cEatanso treet Tar annaised 09} 0.05) 322 0.04 s2q 0.06| 12 124 ea 4a 124 1.24 Particulars 3 months endod 31/12/2013, INVESTOR COMPLAINTS Pendingat the beginning ofthe quarter Received during the quarter Disposed af during the quarter Remaining unresolved at the end ofthe quarter Notes: 1) The above unaucted resus wore reviewed by the Aut Committee and approved bythe Board of Decors a thee respective moetings hold on 14th February 2014 2} The Company i ria engaged in Pharmaceutical formulations business, whch inthe context of Accounting Standard (ASI?) sogment Reporting” fs considered o be the ony business segment 31 The financial results forthe quater ended on 31st December 2013 of the company ae prepared on standalone bass 41 The Company's Bonk Accounts became NPA as indcaed inte previous year. The principal amount due to the consortum of bankers amounied to Appex Rs. 186 rs. The bankers have sent a demand noice under secton 19 af he SARFAESI Actin respect ofthe Company's Assets stated at Vacagaon, Pimp and Vasa for an amount ets, 224 09 Crs that nuded ieee upta Stat jy 2088. The company nes mode Teprasentations for waiver of itarest and grant cf ne fer epaymant af ese aues. The mater 6 pending and the company nae been egaly ‘ised that since possession ofthese uns sti continue wih the company and bw operations are being cared on, toe afrosald Properties continue to remain wth the campany. 15) The non-cansorium bonkers and cher uncacured erodes, have eustanding dues for which they have iad egal proceedings Including wring up petions in various courts. The company has made representation for waiver of itoest and grant of ima for repayment of ese des, 61 In view ofthe fact hat proposal or waiver of intrest is pending wth the banks, no provision for interest forthe period ending 31st Dee 2012 s mad in ‘he accounts. The Banks ate expected ta tke a tinal view on the Company’ representation for a compromise proposal shorty. Cumulative Provision ‘or Conagoncies existing a on 3112/2013 amounting to Rs. 68.60 Cre considorod adequate. Shoal ay, on al setiement weh the Banks Wi be provided fin the accounts in the eneuring peri 71 The company has negotiated vith several rel estate developers fr the monelisation of the company's old plant in Vadapaon and Pimp The gross val of the ral extate cevelopment can achieve resizations in excess of Re. 200 Cre over’ to yore. n adn te company has tented a Strategic evettor with vnom alecussions have reached an advanced slage Tho company seo i in gcuscion withthe bankarsenders for compromise formula fer setement of her duos. On account f these factors be management sof the lew ta continues to operate ae ging concer wih an ably to aly meets obigations. 1 The Board ot Directors of te Company ints mecting hol on 18th May 2013 has approved the proposal to deal, negotate or spate of the whol or par of te Companys manufacturing unt locate at Badd Dist Solan, Himachal Pradesh 4] The current poids figures are not comparable wih the pravious year's figures on account of extension of the accounting yearby the Company. 10] The above resus were subject Limited Review by the Statuary Avalos ofthe Company pursuant fo Clause 41 ofthe Listing Agreement ‘Previous year's flues have been regrouped and rearranged wherever necessary For TWILIGHT UJTAKA PHARMA LIMITED oe Place : Mumbai fl OPAL RAMOURT! Date: 14022016 Managing Director s ee = Asat Stondlon Statement of Assets an iit aiizanta |Asatzo08a019 (Unaudited) (Avaltest) EQUITY AND LIABILITIES oy are Conta rzxeoe] 125008 o) Resume a Supls Jooese| ‘soo ©) Share Aeatien Nonoy (Corrie Wares) 2.00 000 Subtotal -Sharaldore ands ras neeel Shar application mens pening aon oc od Noweatentisies 2) Log Tom eoroninae asooza| ——_aseozs 2) Det abies (nt) ozo] 8820 © Ober 'ong train 0.00 00 d) Long -term provisions 39.57| 39.57| Subtotal -Norcuent bitin haan)